Skip to main content
SleepCited

メラトニン 概日リズム障害

A

合計2,780名の参加者を対象とした104件の研究(メタアナリシス7件、RCT 6件を含む)に基づく。104件中58件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dmelatonin\u0026condition\u003Dcircadian\u002Drhythm\u002Ddisorder'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Melatonin is well-supported by strong evidence as a supplement that may help reset disrupted circadian rhythms and internal body clock timing.

  • 104 studies including 7 meta-analyses and 6 RCTs — one of melatonin's best-studied uses
  • Recognized in clinical practice guidelines for circadian rhythm disorders
  • 56% of studies show clearly positive effects; others show mixed or context-dependent results
  • Research covers delayed sleep phase, irregular rhythms, and non-24-hour disorders

Key Study Findings

Observational Study n=55
Correlation between sleep problems and morning serum melatonin and ferritin levels in Japanese 5-year-old children …
Dose: None vs: None Outcome: correlation between sleep problems and morning serum melatonin … 効果: None p<0.05

対象集団: Japanese 5-year-old children (45 ASD, 10 non-ASD)

Other
An HPLC-MS-Based Method for Determination of the D- and L- 5-Methyltetrahydrofolate Isomer Ratio in Dietary …
Dose: None vs: None Outcome: separation and quantification of D- and L-5-MTHF diastereomers … 効果: None None

対象集団: None

Case Reports n=1 Open-label
A novel CSNK1Dvariant in pediatric advanced sleep-wake phase syndrome.
Dose: None vs: None Outcome: Sleep-wake phase improvement 効果: None None

対象集団: 4-year-old girl with advanced sleep-wake phase disorder

In Vitro
Exogenous L-Cysteine and Its Transport Through CtaP Play a Role in Biofilm Formation, Swimming Motility, …
Dose: 1.57 and 3.67 mM vs: Basal defined media without L-cysteine Outcome: Biofilm formation and motility of L. monocytogenes 効果: None None

対象集団: Listeria monocytogenes 10403S and ctaP mutant

Review
Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment.
Dose: None vs: None Outcome: ISWRD symptom management 効果: None None

対象集団: Patients with irregular sleep-wake rhythm disorder

Key Statistics

176

研究数

4513

参加者数

Mixed

A

グレード

Referenced Papers

Handbook of clinical … 2025 10 件の引用
JAAPA : official … 2025 1 件の引用
Clinical psychopharmacology and … 2024 14 件の引用
Current opinion in … 2024 12 件の引用
Current neuropharmacology 2023 38 件の引用
Journal of clinical … 2023 6 件の引用
Sleep and biological … 2023 6 件の引用
Frontiers in neuroscience 2023 5 件の引用
Neurologia 2022 78 件の引用
Archives of physiology … 2022 69 件の引用
Neurologia 2022 47 件の引用
Current neuropharmacology 2022 40 件の引用
Chronobiology international 2021 47 件の引用
Archives of medical … 2021 6 件の引用
Current topics in … 2021 5 件の引用
Climacteric : the … 2020 97 件の引用
Neurotherapeutics : the … 2020 80 件の引用
Journal of glaucoma 2020 32 件の引用
Current treatment options … 2020 29 件の引用
Human brain mapping 2020 15 件の引用
Current sleep medicine … 2019 28 件の引用
Journal of the … 2019 5 件の引用
Neurologic clinics 2019
Current neurology and … 2018 39 件の引用
Journal of sleep … 2017 1691 件の引用
Current biology : … 2017 455 件の引用
Neurological research 2017 331 件の引用
Continuum (Minneapolis, Minn.) 2017 132 件の引用
Current treatment options … 2017 56 件の引用
FP essentials 2017 15 件の引用
Annual review of … 2016 557 件の引用
Neuropsychiatric disease and … 2016 6 件の引用
Sleep medicine clinics 2015 75 件の引用
Sleep medicine clinics 2015 67 件の引用
Sleep medicine clinics 2015 30 件の引用
Drugs of today … 2015 15 件の引用
Medwave 2015 6 件の引用
Journal of clinical … 2014 19 件の引用
Seishin shinkeigaku zasshi … 2014 1 件の引用
Continuum (Minneapolis, Minn.) 2013 172 件の引用
Nihon rinsho. Japanese … 2013
Chronobiology international 2012 1248 件の引用
Postgraduate medicine 2011
Expert review of … 2010 58 件の引用
Letters in applied … 2010 57 件の引用
The International journal … 2010 55 件の引用
Amino acids 2009 321 件の引用
Travel medicine and … 2009 101 件の引用
Seminars in neurology 2009 17 件の引用
Tidsskrift for den … 2009 6 件の引用
Turk psikiyatri dergisi … 2009
Arzneimittel-Forschung 2008 89 件の引用
Sleep medicine 2007 201 件の引用
Behavioral sleep medicine 2007
The FEBS journal 2006 56 件の引用
Molecular and cellular … 2006 54 件の引用
Journal of biological … 2005 316 件の引用
Seminars in neurology 2004 16 件の引用
Journal of neuroendocrinology 2003 719 件の引用
Best practice & … 2003 339 件の引用
The Cochrane database … 2002 154 件の引用
Revista de neurologia 2002 35 件の引用
Neuro endocrinology letters 2002
The Cochrane database … 2001 154 件の引用
The American journal … 2000 472 件の引用
Medical science monitor … 2000 11 件の引用
Proceedings of the … 1999 96 件の引用
Reproduction, nutrition, development 1999 64 件の引用
Current treatment options … 1999 23 件の引用
European journal of … 1999
Nihon rinsho. Japanese … 1998
Chronobiology international 1997 135 件の引用
Medecine tropicale : … 1997
The Netherlands journal … 1996 13 件の引用
La Revue du … 1996
Journal of psychiatry … 1994 118 件の引用
Cytotechnology 1990 9 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
0.5-3 mg, 30-60 min before bed
jetlag:
0.5-5 mg

上限量: No established UL; 5 mg typically considered maximum

研究で検討された用量

用量 期間 効果 N
None -- Positive 55
None -- Neutral --
None -- Mixed --
None -- Positive 1
1.57 and 3.67 mM -- Mixed --
None -- Mixed --
None -- Positive --
20 mg or 50 mg tasimelteon daily 5 weeks Positive 322

推奨摂取タイミング: 30-60 minutes before bed

Safety & Side Effects

報告されている副作用

  • Daytime drowsiness
  • Headache
  • Dizziness
  • Nausea
  • Vivid dreams or nightmares

既知の相互作用

  • Blood thinners (warfarin) — may increase bleeding risk
  • Immunosuppressants — melatonin may stimulate immune function
  • Diabetes medications — may affect blood sugar levels
  • Sedatives and CNS depressants — additive drowsiness

耐容上限摂取量: No established UL; 5 mg typically considered maximum

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does メラトニン help with 概日リズム障害?
Based on 176 studies with 4,513 participants, there is strong evidence from multiple clinical trials that メラトニン may support 概日リズム障害 management. Our evidence grade is A (Strong Evidence).
How much メラトニン should I take for 概日リズム障害?
Studies have used various dosages. A commonly studied range is 0.5-3 mg, 30-60 min before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of メラトニン?
Reported side effects may include Daytime drowsiness, Headache, Dizziness, Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for メラトニン and 概日リズム障害?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 176 peer-reviewed studies with 4,513 total participants. The overall direction of effect is mixed.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。